Physician global score was the strongest predictor of future flares in AS patients with TNFi dose tapering. 29 (27%) flared at 2/3 of standard dose, 21 (20%) at 1/2 dose, 29 (27%) at 1/3 dose and 27 (25%) after discontinuation @RheumNow #ACR21 Abst#0929 https://t.co/pIzLgexe3k https://t.co/UM9cGLiYl7

• Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare …

Physician global score only predictor of axSpA flares when tapering TNFi ⭐️Changes in imaging did not predict flare Abs#929 #ACR21 @RheumNow https://t.co/vVn6ARKJu0 https://t.co/FlVtlLmTfl

• Tapering of TNF Inhibitors in Patients with Axial Spondyloartritis – Can Flare …

French real-world AxSpA cohort analysis showed drug retention of SEC & TNFi were similar. In subgroups analyses, age, BASDAI at dx & BMI were similar. Abs 0911 #ACR21 #RheumNow @RheumNow https://t.co/ewtmpxKTNu https://t.co/Yh0nX3x83Z

• Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondylo…

#ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA ⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx ▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX). ▶️1/3 of pts achieved LDA Limits: real-world, unblinded https://t.co/AJtzeMuj1T @Rheumnow

• https://bit.ly/3qdAU4s

Dr Jin @SeoyoungCKim population-based study on predictors of switching after 1st line TNFi use. 22% switch, most to 2nd TNFi.👩, prior steroid use predicted change, other autoimmune disease and vit D use negative predictors. Abstr#579 #ACR21 @RheumNow https://t.co/YpZ5rGBiod

@MilenaGianfran @JYazdanyMD present on differential effects of biologics on CDAI in obese patients with rheumatoid arthritis. Abatacept better than TNFi in obese. Tocilizumab better than TNFi in non-obese. Abstr#0588 #ACR21 @RheumNow #ACRBest https://t.co/UcEpMAmNVw

No significant difference in effectiveness/treatment survival of different TNFi in axSpA Failure of 1st TNFi did not diminish effectiveness of a second TNFi Abs#938 #ACR21 @RheumNow https://t.co/SLrOV7wmvU https://t.co/fkpmseVwF6

• Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors fo…

Abstr 0579 Kim & Colleagues examined predictors of Tx change among RA patients w/ TNFi as 1st line biologic agent - Females & GC use more likely to switch agent - Vitamin D use & hx of other immune-mediated diseases (eg. Psoriasis, IBD) less likely to switch #ACR21 @RheumNow https://t.co/FM5mSWmSNA